Companies / Germany
Daiichi-Sankyo Consolidates In Europe
July 2006 | Company Finance AlertJapan's Daiichi-Sankyo is to redouble efforts to expand in Europe. Sankyo alone had sales of EUR322mn (US$406mn) in the region last year. With over 1,000 sales representatives already employed in the region, the company also hopes to benefit from a new co-marketing deal on US firm Eli Lilly's osteoporosis treatment Evista (raloxifene). The arrangement, which marks a new area of therapeutic focus for the Japanese company, will cover the major Western European markets except France, Spain and the
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
